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Abstract
Flow cytometry and cell sorting are critical tools in stem cell research. Recent advances in flow
cytometric hardware, reagents and software have synergized to permit the stem cell biologist to
more fully identify and isolate rare cells based on their immunofluorescent and light scatter
characteristics. Some of these improvements include physically smaller air-cooled lasers, new
designs in optics, new fluorescent conjugate-excitation pairs, and improved software to visualize
data, all which combine to open up new horizons in the study of stem cells, by enhancing the
resolution and specificity of inquiry. In this review, these recent improvements in technology will
be outlined and important cell surface and functional antigenic markers useful for the study of
stem cells described.
Introduction
Stem Cells, Applied Therapeutics and Flow Cytometry
Stem cells are characteristically defined as quiescent, multipotent cells with the capacity for
asymmetric self renewal and differentiation (1,2). The self-renewing capacity of stem cells
ensures the integrity of the various anatomic compartments of the host, throughout its
lifetime. Stem cells have been isolated from numerous anatomic locations and are most
often classified based on the tissue from which they have been purified, and on the types of
cells into which they differentiate. When isolated from their natural milieu and placed within
in vitro culture, stem cells tend to differentiate into mature cells belonging to the tissue of
origin. Their potential in regenerative medicine relies on the understanding of how they
interact with their microenvironment or stem cell niche (3). This protective environment
contains a variety of differentiated cells that secrete factors and fosters an environment that
permit stem cells to both self-renew and/or differentiate along either multiple or individual
lineages.
Over the last decade there has been extraordinary growth in stem cell research and related
applied clinical practices. This has largely followed on the heels of the increasing success of
bone marrow transplantation for the therapeutic treatment of malignancies, as well as
continued progress in solid organ transplantation. Bone marrow transplantation has
demonstrated that stem cell transplantation can have a palpable impact on improved
therapeutic outcomes, and can even be combined with solid organ transplantation for
improved outcomes (4). Complications with long-term immunosuppressive drug therapy,
chronic rejection and the need for greater numbers of solid organs for transplantation than
available have prompted the emerging field of regenerative medicine.
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Equally critical when postulating stem cell transplantation is the immunological safety
associated with the graft. Transplanted stem cell grafts are potentially tumorigenic or
infectious, and must be implanted and tolerated without rejection by the host, or in the case
of hematological grafts, graft versus host disease (GVHD). The theoretical prospect of
possibly transplanting MHC deficient cells must be weighed against both their being prime
targets of host NK lysis and the reality that many lethal human malignancies are those which
have poor MHC expression and thus escape host recognition.
Thus, the study of stem cell biology offers the biologist the opportunity to study the
mechanisms that regulate embryonic and cellular differentiation and tissue maintenance, and
to clarify the molecular and immunological mechanisms underlying this establishment.
Based on the premise of more fully understanding these processes, there is great potential
for enhancing present stem-cell based therapies and developing new ones directed against
degenerative diseases. By extension, with a further understanding of the dysregulation of
stem cell differentiation, it might be possible to gain better perspective into the causes of the
malignant transformation of cells (5). Aiding all of these endeavors has been the technology
of flow cytometry and cell sorting, which continues to play a pivotal role in enhancing our
understanding of these cellular processes.
Flow cytometry offers the ability to examine rapidly thousands of cells stained with
monoclonal antibodies conjugated to fluorescent dyes. Each cell is individually assessed for
a variety of characteristics such as size and biochemical and/or antigenic composition. High
precision and sensitivity, combined with the large numbers of cells that can be examined
permits resolution of even very minor subpopulations from complex mixtures with high
levels of statistical validity. The capacity to physically separate these subpopulations by
flow sorting allows further functional, morphological and molecular correlations to be
determined.
Since the inception of flow cytometry and fluorescence activated cell sorting in the mid to
late nineteen sixties (6,7,8,9,10) the technology, coordinated with progress in monoclonal
antibody production, has become incorporated into fields encompassing predominantly
human clinical medicine and biomedical research. This has primarily been in areas of
immunology, pathology, oncology and molecular biology, such as the diagnosis of
hematopoietic malignancies and monitoring of HIV/AIDS and other research areas related to
cell signaling, viability and apoptosis. However, cytometry has additionally found use in
veterinary medicine, agricultural, oceanic and even astronomical research. It is widely
accepted that the technology has provided a critical impetus to modern immunology and
proteomics and is a cornerstone of current stem cell research. Just as each of the
aforementioned disciplines requires modifications and specific alterations of the basic
technology, the use of cytometry in stem cell research also has unique requirements.
Numerous reviews and books are available to begin to learn about the technology related to
flow cytometry and cell sorting (11,12,13,14,15,16,17). In this review, we will delegate
these available reviews and books to update the reader on ‘the basics’ of cytometry and
concentrate on relatively newer technologies related to instrument design and advances in
reagents and analytic software. There will also be an overview of important cell surface
antigens and functional markers that are available for flow cytometry that have been useful
for stem cell research.
While routine ~4-color flow cytometric analysis has been effectively utilized for research
and clinical analysis for many years, recently our laboratory and others have been exploring
the potential of greater immunofluorescent capacity for stem cell research. With new
concept instruments, reagents and software similar to that described below, we aspire to take
this capacity to yet a higher level. While these technologies are presently in their nascent
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stages, advances in research have been forthcoming (15,18,19,20) forecasting their practical
utility in stem cell research, with eventual emergence into the clinical diagnostic setting
(21). The use of polychromatic (>5 colors) cytometry has been made possible by advances
in three technically interrelated areas:
1] Introduction and general commercial availability of appropriately
configured cytometric hardware with multiple excitation sources, highly
sensitive collection optics and digital electronics—High quality multilaser
platform instruments started becoming commercially available beginning around 2002.
These instruments contained air-cooled diode-pumped solid state and laser diodes, high
efficiency optics, electronics and fluidics which all combined to both improve the resolution
and efficiency and reduce the cost of high quality analyzers. For example, prior to these key
advances, the requirement for high-power ultra-violet ion-laser sources, and their related
expensive infrastructural support inhibited the study of side population (SP) cells and other
assays requiring ultra- or near violet excitation (22,23). This successful platform design
combination also forecast similar advances in cell sorter assembly, permitting smaller
footprint cell sorters that were as capable or in some ways even superior to their physically
larger predecessors. For example, in some designs, utilization of flexible fiber optics to route
signals from the flow cell to PMT arrays provided overall greater design adaptability.
2] Increased commercial availability of monoclonal antibodies directed to
leukocyte differentiation antigens conjugated to fluorochromes with
excitation maxima proximal to multiple available excitation sources—Until
recently it was extremely difficult to obtain monoclonal antibodies conjugated with anything
other than 488nm and 632nm –excited fluorchromes from commercial sources; fortunately
the availability of other fluorochromes conjugated to antibodies have expanded significantly
in the last few years. Fluorochromes chosen should have high extinction coefficients and
quantum yields, be easily conjugated to monoclonal antibodies and have little spectral
overlap with other conjugates. Beginning at the ‘most violet’ end of the spectrum, the UV-
excitable Alexa 350 and AMCA-X fluorochromes can be conjugated to monoclonal
antibodies, and serve as potential labels. Although not useful for antibody labeling, but
helpful since the inception of flow cytometry, Hoechst 33342 is required for side-population
studies (24,25) and 4′, 6-Diamidino-2-phenylindole dihydrochloride (DAPI) is useful for
cell cycle and/or DNA-ploidy studies. Useful conjugatable violet [~405nm] excitable dyes
include AmCyan 403, Pacific Blue, Pacific Orange, Alexa 405, Alexa-430, V450 and a
variety of quantum dots [e.g. Qdot™, eFluor™, AxiCad™ nanocrystals]. Quantum dots
[semiconductor nanocrystals] did not initially easily conjugate to monoclonal antibodies and
when unbound were prone to aggregation, but have recently improved in performance. Blue
[~488nm] excitation is best for FITC, Cy3 and peridinin chlorophyll protein (PerCP). PerCP
is similar in emission to the tandem PE-Cy5, with less red spillover than the tandem.
However, PerCP conjugates are ‘bleached’ easily and thus cannot be used with the higher-
power argon-ion lasers commonly found on stream-in-air cell sorters. Green [~532nm] or
preferably yellow-green [~565nm] excitation lines are best for phycoerythrin (PE) excitation
and red [~633nm] for allophycocyanin (APC) and both their respective tandem-conjugates
of Cy5, Cy5.5 and Cy7. Tandem dyes, which rely on the resonance energy transfer between
closely approximated donor and acceptor fluorochromes tend to have a propensity for non-
specific binding, instability and lot-to-lot variation even when obtained from one source, and
thus also must be used cautiously. Recently, HiLyte 750 has been shown to be useful when
used as a tandem conjugate with APC since it is more stable to light exposure than Cy7,
which significantly reduces spillover into the APC channel. Somewhat more esoteric, but
useful conjugates of Alexa 594 and LI-COR IR-Dye 800CW can be used with yellow and
infra-red lasers, respectively (Figure 1). Very low background fluorescence in the IR range
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provides for a much higher signal-to-noise ratio than visible fluorophores, which helps
compensate for the relatively lower photon counting statistics in the far-red region. In the
future, the use of avalanche photo-diodes to capture these far-red emissions may prove to be
superior to anything but the most red-sensitive PMTs (26).
3] Operational and analytic software capable of functioning in the digital
domain, permitting the numerous required intra- and inter- laser fluorochrome
compensation calculations—Due to the complexity of compensating polychromatic
fluorescent signals it is essential to rely on software-based matrixes that can objectively
adjust the compensation settings after the data is collected and apply bi-exponential scaling
(27). While software has matured well enough to tackle this particular need, currently
available analytic software is still relatively primitive in fully exploiting the potential of
polychromatic analysis, with respect to ‘data-mining.’ That is, although the software is
functional, it is suboptimal in that compared to 3–4 color analysis, most existing software
platforms scale poorly when larger polychromatic data-sets require processing; ‘data-
mining’ then becomes a very time consuming process. Furthermore, the voluminous number
of bivariate plots resulting from the analysis of a polychromatic data set tends to inhibit
rather than help inquiry. Additionally, “gating” remains a relative subjective process with
the potential loss of data, especially when numerous gates are applied.
While the convergence of the aforementioned improvements in hardware, reagents and
software permit our present capacity, the techniques to reproducibly stain cells with ≥10–12
directly conjugated fluorochromes is presently at a relatively early stage. Although the initial
step of consulting a table of dye excitation and emission maxima and matching these to
band-pass filters and excitation sources is necessary, it is insufficient to attain reliable
polychromatic capacity without equal and strict attention to issues related to reagent
titration, potential dye-dye interactions, fluorescence compensation and staining controls
(15,17,28). Our initial results years ago using stream-in-air cell sorters were initially
disappointing when attempting resolution of ~7 markers; however, after access to the light
collection improvements inherent in cuvette-design technology, many of the problems were
quickly surmounted. For example, the increased optical efficiency inherent in a gel-to-
objective-coupled cuvette over cell interrogation through a ‘lens-like’ stream-in-air sorter
provided a superior signal. While the need for controls and compensation matrices presently
require more care than routine 4-color work, these obstacles have been reasonably
surmounted, as indicated, with improved software. Cumulative and incremental
improvements in achieving maximal signal-to-noise ratios for each fluorochrome, such as
optimized optical filter selection and refining detector voltages were additionally helpful.
Increased awareness of fluorescence detector performance and tools with the capacity for
measuring and tracking cytometer resolution [Q =efficiency, and B= background] also serve
to improve the quality and reproducibility of instrumental measurement (29,30).
Table 1 indicates the excitation and emission characteristics of some of the fluorescent
conjugates and probes and commonly used excitation lines we find useful:
New Technology- Multi-Laser Cytometers: Access to cytometers with more than two-three
lasers is becoming common place
Recently, our laboratory has constructed a unique prototypic 7-laser instrument (Becton
Dickinson, San Jose CA). The instrument is both stable and highly configurable, which is
valuable in a varied research setting where flexibility in excitation source wavelength plays
a critical role. This instrument permits us to fully exploit new reagent combinations and seek
laser/dye combinations with minimal compensation between fluorochromes. The new
concept is to improve measurements (photon counting statistics) by combining increased
Preffer and Dombkowski Page 4
Cytometry B Clin Cytom. Author manuscript; available in PMC 2010 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
laser powers (e.g. up to 100 mW at 488 nm) and multiple laser excitation line flexibility
with enhanced optical collection efficiency to minimize measurement error and improve
resolution of relevant biological populations. Furthermore, to increase flexibility, optical
switchboxes can redirect the emission light paths between different fluorescence collection
optics configurations containing either 8 (octagon) or 3 (trigon) PMT channels.
The instrument is configured with the following lasers and PMT arrays, arranged as depicted
in Figure 2:
This instrument’s design permits choice of selected antibody-fluorochrome combinations
that require minimal compensation, in part by permitting a theoretical reduction in the
number of fluorochrome excitations per laser to ~2. That is, rather than simultaneously using
every possible fluorochrome that the green laser can excite, we choose among conjugated
probes spread throughout a wide excitation spectrum to minimize inter- and intra- laser
compensation needs, increasing the resolving power of the instrument (Figure 3). The
appropriate integrated use of these 7 excitation sources with suitable fluorochromes permit
reduced spillover correction/compensations between all fluorescent parameters, in contrast
to using relatively fewer excitation lines and more fluorochromes per line. A high efficiency
quartz cuvette captures and directs seven temporal and spatially discrete signals via distinct
fiber-optics to seven PMT populated arrays. The PMT-populated octagonal arrays provide
the flexibility to use present antibody-fluorochrome conjugations as well as anticipated new
fluorochromes in the future (31,32,33). New fluorochromes for immunophenotyping
applications are consistently being developed, such as violet excitation of quantum dots
conjugated to monoclonal antibodies (34,35,36) eFluor crystals, UV (AMCA-x) and infrared
(IRDye 800CW) dyes. Further flexibility in excitation sources might be obtained in the near
future with a new family of rare-earth [Tm3+ and Yb3+] ‘up-converted’ nanophosphors
which will open up the infrared region to flow and image cytometry (37).
Cytometric Data Representation: Present Software Limitations and Solutions
Presently, flow cytometry data is most commonly depicted on two dimensional “x versus y”
Cartesian dot- or contour -plots, with a possible third dimension in the z-plane identified
with color as a sign of density or relationship to a gated parameter(s). The goal of any and
all analytic software should be to aid the researcher by providing the most concise data for
either cell sorting or analysis. There are a variety of commercial approaches to this from the
numerous instrument manufacturers [e.g. Accuri, Beckman Coulter, Becton Dickinson,
Guava, Partec. Additionally, ‘third party” approaches to data analysis are available from De
Novo, Tree Star, VenturiOne™, and Verity Software, as well as numerous open source
products [e.g. WinMDI, IDLYK, ANALYSE and LAP].
Multiparameter or polychromatic populations require complex Boolean gates or multiple,
hierarchical gates to resolve desired subpopulations. The logarithmic axes generally extend
over a four to five decade range, representing cells with 10- to 100- thousand fold intensity
disparities between the least and most expressive cells. These plots are easy to inspect and
enjoy wide acceptance by the scientific community. While such data representation is
acceptable and sufficient for inspection of ~ 4–5 multiparameter fluorescent parameters, the
number of bivariate plots quickly increase to an unwieldy number with polychromatic data;
the total number of bivariate plots needed to project P parameters is P × (P−1)/2. For
example, use of 4 immunofluorescent parameters results in 6 bivariate plots to examine;
however if 17 markers are used there are 136 bivariate plots to inspect. This makes total
comprehension of such information very difficult and inhibits an overall understanding of
the data, due to the voluminous number of histograms requiring inspection. To attempt to
break from the ‘Cartesian handcuffs’ of multiple bivariate plots, totally new ways of
representing the data output of flow cytometers are emerging, incorporating alternative
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approaches such as mixture modeling (38), cytometric fingerprinting (39), statistical
manifolds (40) probability binning (41) use of heat maps and FCOM™-like additions (42). A
further expanded repertoire of software tools are also emerging such as:
The parallel coordinate plotting system which is a graphical device for displaying data in
high-dimensional space above three dimensions, and is also an alternative to the
conventional scatter plot. Since plotting more than 3 orthogonal axes is difficult to represent
in 2 dimensions, parallel coordinate schemes represent each parameter as a discreet axis and
plot all the axes parallel to each other in a plane. In these plots, orthogonal axes are replaced
by drawing the uniformly spaced axes parallel to each other such that each cytometric
parameter has a unique representation. This results in improved ‘scalability’ compared to
traditional bivariate dot-plots, resulting in a relatively compact two-dimensional
visualization of the polychromatic data set (43,44). To address some of the problems with
visualizing huge data sets, the two-dimensional data can be clarified by adding an iso-
surface in the z-dimension denoting the density of events or as a ‘gating’ tool analogous to
that used in Cartesian dot-plots (45) or by utilizing feature animation or high precision
textures (46). This approach is being developed in our laboratory as an exciting and helpful
new way of addressing the need for an improved method of inspecting large polychromatic
data sets, as shown in Figure 4.
Another novel presentation tool is the polyvariate display function (FlowJo;Tree Star, Inc.)
which is another way to display more than 2 parameters on a 2D graph, permitting the user
to define complex populations of cells using one gate. This tool uses a vector control and
pivot range integrated with the polyvariate plot whereby the origin is the center of a circle;
the origin is the minimum value and the circumference is the maximum value. The vector
angle determines the direction away from the origin the parameter will be scaled as shown in
Figure 5.
A third novel approach currently under development incorporates a probability state model
(Gemstone; Verity Software). This is a new concept which avoids the pitfalls of numerous
bivariate plots in favor of a newly conceived scalable display tool. The software avoids
gating problems by defining overlapping populations probabilistically (47). The model
defines a ‘state index’ which is an additional parameter based on states and probabilities.
This parameter is used to correlate all the other parameters in the system and results in the
ability to analyze multiple samples in a compact and comprehensible format (Figure 6).
With a properly configured antibody –fluorochrome design, the software will also permit
additive/concatenated staining so that common elements between staining tubes will serve as
a scaffold to permit unique correlations between tubes to be viewed. The software can
potentially serve as a sorting interface, making use of its unique analytical capacity to more
easily and expeditiously identify complex immunophenotypes.
Promising Cell Sorting Technologies with an impact on applied stem cell research
Although high-speed hydrodynamically focused stream-in-air cell sorting is presently the
gold-standard cell separation technology, there are numerous reasons why it is an
impractical way to select large numbers of stem cells for potential large scale therapeutic
use. Firstly, because conventional droplet sorters inspect cells serially they are intrinsically
too slow to isolate large numbers of cells and their use risks both sample contamination and
operator exposure to potentially hazardous material. One approach to enhance the speed of
analysis is to increase the number of droplet sorters operating in parallel on the experimental
sample, exemplified by the approach of the iCyt™ Reflection, which scales up to four
sorting heads per instrument. Another prospective improvement would utilize a laser
rastering system, in which an excitation beam of reduced width is rastered across the core
stream, capturing cells from every portion of the stream. The design insures that every cell
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would be repeatedly scanned to both limit cellular coincidence and increase performance
throughput over conventional systems by five fold (48).
Rather than using sheath fluid to hydrodynamically focus cells, it is possible to focus and
concentrate them using acoustic excitation. There are practical advantages to omitting sheath
fluid including significant cost and instrument-size savings, in addition to the ability to
repeatedly reanalyze cells for reliable rare event analysis (49).
In contrast to droplet sorting, the micro-fluidic switch sorting technology does not require
droplet formation and can take place within an entirely enclosed sterile and disposable
fluidic path. However, micro-fluidic switch sorting has been relatively slow (~ 200 cells/
second) compared to conventional high-speed droplet sorters operating at an upper range of
~25–35,000 cells/second (50).
Two important recent developments have dramatically increased the overall cell sort rate in
micro-fluidic switch sorting. These are a 10-fold increase in sort rate and parallel
implementation of multiple switches on a single disposable chip. The disposable chip is
embedded in a single-use, disposable cartridge that contains the entire fluid system of the
flow sorter (51). This emerging technology (e.g. the Gigasort™ from Cytonome) overcomes
the limitations in switch-sorting cell processing speed, selection capability and cGMP
compliance and will enable sample throughput rates of up to 1×109 cells per hour (~280,000
cells/second). It is likely that future cell separation techniques will capitalize on further
advances in microfabrication which will serve to both shrink the size and cost of
instrumentation, while vastly increasing their scalability and capability up to 32 fluorescent
parameters (52), resulting in high-throughput ‘lab-on-a-chip’ instruments (53,54).
While stream-in-air sorting remains the gold standard for rapidly separating cells in
suspension, it is of more limited utility for small numbers of adherent, biohazardous and/or
fragile cells. Other issues related to both altered gene expression and physiology related to
detaching adherent cells can also limit the utility of cell sorting. Thus, it is worthwhile to
mention laser-enabled analysis and processing (LEAP™) technology, which can image and
purify adherent cells by a variety of laser-mediated cell manipulations in a high-throughput
fashion (55).
Although not a cell separation technology, it is worth noting that the combination of flow
cytometry and quantitative cell imaging has been accomplished in the Amnis ImageStream™
system. This technology has recently improved its capacity to visualize cells with an
enhanced depth-of-field technology and has been involved in advancing stem cell research
in areas related to Wnt signaling (56), leukemic stem cells (57), pluripotent stem cells (58)
as well as helping define ‘very small embryonic-like stem cells’ (59).
II. Antigenic and Functional Markers Useful for the Study of Stem Cells
Stem cells are characteristically identified by cell surface or functional markers, or
combinations of the two, by flow cytometry. Since stem cells are profoundly scarce, when
attempting to analyze or physically separate them based upon multiparametric
characteristics it is extremely useful to physically remove fully differentiated cells with
‘mature’ cell markers. For example, in separating hematopoietic stem cells from human
bone marrow, cord or peripheral blood, it is often best to initially apply biotinylated
conjugated cocktails of CD45, CD3, CD4, CD8, CD19, CD56, CD16, CD14, CD33, CD11b,
CD61, and CD71. In the mouse, analogous markers including B220, Mac-1, Gr-1, CD4,
CD8 and Ter119 are best utilized (60). These labeled cells are then removed by parallel
‘negative selection’ sorting with streptavadin conjugated paramagnetic beads in a strong
magnetic field, resulting in a lineage negative (Lin−) population that can be subsequently
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labeled for serial ‘positive’ selection or identification by flow cytometry. Various manual
and automated systems are commercially available for this step (e.g. Miltenyi, Dynal,
Robosep, IMag). The benefit of this procedure is that cells otherwise present at ‘fractions of
a percent’ can be more effectively positively identified and/or sorted with increased levels of
purity and recovery. A pitfall is that extremely rare cells may be nonspecifically “trapped”
by numerous differentiated cells during the magnetic bead sort. When desired rare
subpopulations are relatively better represented, rather than their physically separation, Lin+
cells can be relegated into a fluorescent ‘dump channel,’ in which all Lin+ cells are stained
with the identical fluorochrome. Then, antigenic co-expressions are more easily visualized
on rare cells without impediment by differentiated cells. Some of the technological advances
in the previous section, such as the increased analytical sensitivity and precision afforded by
the use of multiple higher power solid state lasers, become extremely useful in obtaining this
information.
A complete review of stem cell immunophenotyping is beyond the scope of this review;
however, as an aid to those relatively new to the field, Table 2 illustrates some antigens
which have primarily been useful in the study of human and murine hematopoietic and other
stem or progenitor cells. Following the table are further specifics in an ‘antigenic approach’
to these and other functional markers, in some cases including murine studies which were
helpful in the development and further understanding of progenitor, stem and cancer stem
cells.
Lineage negative, cKit+, SCA−1+ (LKS)
Initially, hematopoietic stem cells (HSC) were defined in the murine system by the
combination of the absence of mature lineage antigens CD4, CD8, Ter119, Gr-1, Mac-1
(Linneg), the presence of stem cell antigen expression (SCA-1+) and reduced expression of
the Thy-1 (Thy-1lo) marker (61,62,63). This initial approach was subsequently modified
with the use of the tyrosine kinase receptor CD117 (c-Kit), CD34 negativity, the membrane
glycoprotein CD135 (Flt3) and CD150 expression to help distinguish hematopoietic stem
cells (Linneg - c-Kit+ SCA-1+, Thy1.1lo, CD34-, Flt3−, CD150+, CD244−) from
multipotent progenitors (Linneg c-Kit+ SCA-1+, Thy1.1lo, CD34+, Flt3+, CD150−
CD244+ ; 64,65,66). It remains that these marker combinations are very useful, but likely
describe overlapping populations, especially when dye efflux capacity {vide infra} is added
as a functional parameter. Thus, it is prudent to recognize that there is presently no standard
in distinguishing stem from progenitor cell populations especially when strain, animal
developmental age and potential mutant mouse models are considered. For example, Thy1
expression is only useful in strains carrying the allele, and selection based on CD34-
requires the use of mice >8 weeks old. These complications are further compounded when
considering the use of mutant murine strains, the technical staining competency and the type
of cytometry equipment used.
CD34 is a stage-specific antigen that is expressed on human hematopoietic stem and
progenitor cells whose expression decreases with differentiation of the cell. Human CD34
can be divided into three broad classes (I, II and III) of recognizable epitopes based upon
their sensitivities to neuraminidase and the O-sialoglycoprotease from P. haemolytica (67).
Selection of a properly titrated antibody and fluorochrome-conjugate is essential to obtain
valid information since not all classes of antibody uniformly stain the antigen. For example,
most Class I antibodies have lower avidities and are not recommended for use in
immunodiagnostic panels. In contrast, PE-conjugates of Class III (e.g. clones 8G12, 581)
and Class II (QBEnd10) detect identical populations. However, FITC conjugates of
QBEnd10 do not have the same reactivity, likely due to inhibition by the negatively charged
glycan target and the negative charge conferred to the antibody by the FITC conjugate (68).
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CD34+ cells are heterogeneous and their co-expression of other markers such as CD38,
CD123, HLA-DR, CDCD45RA, CD71, CD90, CD117, and Rhodamine123 have been used
to distinguish subpopulations enriched in progenitor populations (69). For example, subsets
of CD34+ CD109+ cells obtained from fetal and adult bone marrow have been shown to
define pluripotent megakaryoblast and myelo-erythroid progenitors (70). Recently, human
HSC obtained from cord blood have been identified as Linneg
CD34+CD38−CD90+CD45RA− and were distinguished from Linneg
CD34+CD38−CD90−CD45RA− multipotent progenitors using both xenotransplantation
and in vitro assays (71).
Murine CD34 has been shown to have similar biochemical and functional properties with a
similar cellular distribution as human CD34 (72). Although CD34 knockout mice contain
reduced numbers of hematopoietic precursors the animals have normal bone marrow and
peripheral blood counts, pointing to a redundancy in CD34 function with some other cell
type (73).
SLAM—While the Linneg c-kit+ Sca-1+ Thylo markers have been the defacto standard for
murine stem cell isolation, the aforementioned problems regarding the complexity of their
use as well as the sheer number of antibodies necessary presents an impediment to
researchers, particularly for tissue based studies. The signaling lymphocyte activation
molecule (SLAM) family of markers represents another resource for studying stem cells by
flow cytometry. Reduced numbers of these markers in ‘coded’ combinations were reported
to distinguish hematopoietic stem cells (SLAMf1/CD150+ CD244− CD48−) from
multipotent (CD150− CD244+ CD48−) and B cell (CD150− CD244+ CD48+) progenitors.
Moreover, the code of SLAM expression was found to be conserved among different and
older mouse strains even if transplanted (74,75). Like many of the aforementioned markers
described, there is likely significant overlap between these and other putative surface and
functional stem cell markers.
CD133—(AC133 or Prominin-1) is a surface molecule expressed on primitive human
progenitor cells of hematopoietic, endothelial, and neural epithelial lineages (76,77,78).
CD133 is a 5-membrane–spanning cell surface molecule that does not share homology with
previously described HSC surface antigens and is rapidly down-regulated as human HSCs
differentiate into phenotypically restricted cells (79). Compared to CD34+CD133−cells
obtained from cord blood, CD34+CD133+ cells were found to have much increased
clonogenic and repopulating capacity when injected into NOD/SCID mice, and had seven-
fold enrichment in functional dendritic cell precursors (69) and LTC-IC function. CD34+
CD133+ cells preferentially gave rise to granulocyte-macrophage colonies while
CD34+CD133− cells produced erythroid colonies (80). Because cultured CD34−CD133+
cells isolated from cord blood have the capacity to generate CD34+ cells, it is hypothesized
that the CD34−CD133+ immunophenotype might be ancestral to the CD34+ subpopulation
(81). When peripheral blood CD133+ cells were cultured on fibronectin coated dishes in the
presence of vascular endothelial growth factor, endothelial cells resulted from cells that
initially expressed CD31+ (82). Neurons, astrocytes and rare oligodendrocytes resulted from
adult and fetal human skin derived CD133+ cells, which also demonstrated self-renewing
capacity. These cells, which co-expressed CD34+ and CD90+, were grown in medium
containing epidermal and fibroblast growth factors and could implant and differentiate in
adult mouse forebrain. Although unproven, it is possible that these skin derived CD133+
cells were derived from the blood (83). Another molecule found on normal and malignant
hematopoietic CD133+ and CD34+ cells obtained from bone marrow, cord or peripheral
blood is CD318 (CUB-domain-containing protein 1, or CDCP1). Interestingly, this antigen
is also detected on mesenchymal and neural progenitor cells, suggesting it’s possible role as
a multipotent adult progenitor cell marker (84).
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CD117 also known as c-kit, steel factor, or stem cell factor (SCF) receptor/ligand is a proto-
oncogene encoding a 145 kd tyrosyne kinase transmembrane receptor which plays a key role
in haemopoiesis and belongs to the same family of receptors as platelet-derived growth
factor and colony-stimulating factor-1 (85). In human bone marrow and cord blood CD117
is expressed on early myeloid progenitors and is down-regulated upon maturation, except on
mast cells. Due to this characteristic expression, CD117 is especially useful in the
differential diagnosis of acute myelogenous leukemia from acute lymphoblastic leukemia in
the clinical flow cytometry laboratory. CD117 was first identified as the cellular homolog of
the feline sarcoma viral oncogene v-kit (86).
The binding of SCF, which is produced primarily by marrow stromal cells to CD117 (87)
leads to the dimerization of c-kit proteins, which initiates a signaling cascade that ultimately
induces cell growth (86). CD117 is thus suggested to be involved in signaling, activation,
and proliferation of cells and is found on a diverse group of histologically normal non-
lymphoid cell types, such as breast epithelial cells, renal tubule cells, astrocytes, Purkinje
cells, and endometrial cells (88).
Mutations in CD117 have been found to play a role in oncogenesis in a large number of
neoplastic disorders such as systemic mastocytosis, gastro-intestinal stromal tumors
(GISTs), germ cell tumors and acute myelogenous leukemia (89). Recent therapies (imatinib
mesylate, or Gleevec) inhibiting specific mutations in the tyrosine kinases such as Bcr-Abel
and the platelet derived growth factor receptor have been shown to be effective in treating
malignancies that over-express this receptor such as chronic myeloid leukemia (90). This
drug is also effective in therapies associated with CD117 expressing GISTs (89,91).
CD90 or Thy-1 is a 25–37 kDa N-glycosylated, glycophosphatidylinositol anchored highly
conserved cell surface protein, originally discovered as a rodent thymocyte antigen with a
possible role in cellular activation. In mice it serves as a hematopoietic stem cell, pan-T,
thymocyte, fibroblast and neural cell marker. In humans, Thy-1 expression appears more
restricted, and is found on a small population of cortical thymocytes neurons and hepatic
stem cells (92,93).
CD105—CD105 is a 180 kDa homodimeric transmembrane glycoprotein expressed
predominantly on the cell surface of human endothelial cells and is thought to play an
important role both in angiogenesis and hematopoiesis (94). The normal function of CD105
is associated with that of the transforming growth factor (TGF)-β receptor and is seen to
significantly up-regulate on vascular endothelium in areas of inflammation and tumor
growth (95). For human stem cell research, the combination of CD105+, CD73+, CD16+,
CD90+ CD29+ CD34−, CD45−, CD14− has been useful in the purification of mesenchymal
stem cells (MSC). MSC have the capacity to differentiate into bone, cartilage and fat and
have been shown to have significant suppressive effects on the immune system of an
allogeneic transplanted host, such as reversing GVHD (96). The mechanism of this
immunosuppressive effect has been specifically related to altered cytokine secretion and
concomitant reduction in inflammatory mediators within subsets of dendritic, T and NK
cells (97).
CD135—FMS-like kinase-3 (FLT3) or STK-1, or Flk-2 is a member of the receptor
tyrosine kinase type III family that also includes c-kit, c-FMS, and PDGFα/β. CD135 is a
growth factor receptor and signaling through it plays a role in cell survival, proliferation,
and differentiation. FLT3 expression in human bone marrow is restricted to CD34+ cells and
a subset of dendritic precursors. CD135 is a proto-oncogene and internal tandem mutations
of FLT3 play an important role in leukemogenesis; such mutations are associated with poor
prognosis in acute myeloid leukemia (98).
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In the murine system, the loss of CD90/Thy1 and gain of CD135/Flk2 expression marks the
loss of self-renewal in HSC maturation. CD135 is expressed in short-term -HSCs but not
long term –HSCs (99).
Functional Stem Cell Markers
Aldefluor is a non-immunological reagent that has been used to identify human stem and
progenitors in the bone marrow, mobilized peripheral and cord blood on the basis of the
cytosolic aldehyde dehydrogenase (ALDH) activity in these cells. ALDH is found in
primitive hematopoietic cells and converts the non-polar, membrane-diffusible substrate
(bodipy- amino-acetaldehyde) into a negatively charged non-diffusible fluorescent bodipy-
aminoacetate. ALDH serves as a ‘de-toxifying’ agent and confers stem cell resistance to
alkylating agents such as cyclophoshphamide (100) as well as oxidizing vitamin A and
ethanol (101). Additionally, since the polarized moiety can only be retained by cells with a
patent cytoplasmic membrane, only viable cells are pinpointed. Similar to Hoechst
exclusion, use of this reagent opens up a strategy of stem cell isolation based upon a
relatively conserved stem cell function rather than an immunophenotype.
ALDHbright+ Linneg cells have been shown to include an enriched expression of
CD34+CD38−, CD133+ CD31+ and CD117+ (102) cells suggesting the presence of both
hematopoietic and endothelial progenitors. These include functional populations capable of
becoming colony forming cells, long-term culture initiating cells and NOD/SCID
repopulating cells.
Relatively distinct hematopoietic compartments have been defined by use of aldefluor as a
marker for ALDH activity with CD34+ umbilical cord blood (UCB) cells. Purified
ALDHbright+ CD34+ cells injected into NOD/SCID mice or placed in primary and secondary
long-term culture were highly enriched for cells giving rise to multilineage development. In
contrast, ALDH−CD34+ or ALDHbright+CD34− cells contained few progenitors (103).
Similar studies using ALDH bright+ CD133+ Linneg cells obtained from UCB seeded the
murine BM microenvironment within 48 hours after transplantation, expanded efficiently in
vivo to produce mature myeloid and lymphoid progeny. These cells also continued to
maintain a population with primitive hematopoietic phenotype, and consistently engrafted
recipients of serial, secondary transplants, unlike their ALDH bright+ CD133- Linneg
counterparts (102).
Due to both the rarity of primordial neural stem cells (NSC) and absence of specific markers
relative to those available in the hematopoietic system, ALDH activity has also been
pursued in the study of neural stem cells. ALDHbright+ SSClo cells obtained from murine
embryonic forebrain germinal zones and adult forebrain subventricular zones were multi-
potent and capable of self-renewal and generation of neurospheres and neuroepithelial cells.
Upon transplantation into mouse brain, progeny of ALDHbright+ cells differentiated into
mature neurons detected in cortical and subcortical areas (104). Cells isolated from the
caudal neural tube of embryonic rats were also found to express elevated levels of ALDH
(105). ALDHbright+ SSClo cells isolated from embryonic and adult spinal cord were also
shown to be self-renewing and multipotent, and could restore partial function when
transplanted intrathecally into a mouse model of spinal muscular atrophy (106).
Hoechst 33342—Hoechst 33342 is a live-cell permeant dye that binds into the minor
grove of A-T rich regions of DNA (107). The dye is best excited by 350–360nm ultraviolet
light and was initially useful in measuring cellular DNA content and proliferation in live-
unfixed cells (108). Side population (SP) cells are stem and early progenitor cells identified
as a subpopulation by their low Hoechst blue and red fluorescent emission signature. This is
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evidenced as a trail of decreasing Hoechst fluorescence from a greater number of more
differentiated cells, with increased fluorescence, that have loaded and retained the dye.
When detecting SP cells, fluorescence is directed towards a 610nm dichroic and then
captured simultaneously through both a 450nm band-pass and 675nm long-pass filter on a
linearly amplified fluorescence scale. The characteristic Hoechst fluorescence SP ‘tail’
(Figure 7) is attributed to a highly active efflux of Hoechst 33342, via a p-glycoprotein
multi-drug/ATP binding cassette transporter Bcrp/ABCG2 protein (24,109,110). The ATP
transporter is otherwise thought normally responsible for biliary excretion, lipid
translocation, and drug elimination.
The result of the high level of dye exclusion is that the fluorescence intensity of the nuclei in
the resultant SP cell population is reduced relative to that in the nuclei of cells in the
differentiated cell population. The presence of the pump is tested by its blockade with a
specific metabolic inhibitor, such as verapamil or reserpine.
The SP staining protocol is relatively rigorous with dye concentration, incubation time and
temperature relatively stringent; after staining, the cells must be maintained at 4°C prior to
processing on the cytometers (107,111). It is very useful to include a viability dye (e.g.
propidium iodide or 7-AAD) to discriminate dead from viable cells. Since the initial staining
protocol was developed for isolating murine stem cells, the staining parameters might need
to be optimized for other tissues or species (25,112).
Murine SP cells were initially defined by their relatively active efflux of Hoechst 33342,
with the cells having the strongest dye efflux ability also having the highest hematopoietic
repopulating capacity (113,114). Bone marrow derived SP cells were shown to be enriched
1000 fold for in vivo lymphoid and myeloid hematopoietic reconstituting activity. These
earliest studies showed SP cells to be about 10% of the Sca-1+ CD34− murine BM,
expressing CD117, CD43, and CD45 (113). Cell cycle analysis of SP cells revealed their
relative quiescence; the few SP cells in growth phase [<2%] had repopulating capacity
indistinguishable from those in GO/1. More recently, cells with this functional capacity have
been further characterized with the SLAM surface marker CD150, with both CD150− and
CD150+ SP subpopulations contributing to distinct lineages that demonstrate distinct
proliferative states (115).
Attempts to enrich for SP cells using other surface markers have resulted in the observations
that CD9 did so in the porcine system (116) and Tie2+ cells obtained from murine bone
marrow also highly enriched for SP+ hematopoietic stem cells. Tie2 is a receptor tyrosine
kinase also expressed on endothelial cells. In adult murine bone marrow, Tie-2+ cells were
shown to adhere to ligand (angiopoietin-1) expressing osteoblasts at the surface of trabecular
bone (117), supporting the concept of the hematopoietic stem cell niche at that location
(118,119). Other studies have shown that murine SP cells could be enriched about 5-fold by
use of the surface marker CD105+ (endoglin), which was identified by a novel
oligonucleotide microarray analysis only requiring 1 ng of RNA. More recently, it was
reported that the reconstitutive activity of murine SP cells could be enriched in cells
expressing the endothelial protein C receptor CD201 on the cell surface (120). This marker
was discovered by comparison of the differential gene expression profile of purified versus
non-SP cells using Affymetrix microarrays.
SP cells have been obtained from numerous solid tissue sources and species (113,121). For
example, SP cells identified in the murine lung appear to have both mesenchymal and
epithelial potential (122). In other studies, SP cells obtained from murine muscle were
shown to express Sca-1, but lacked the CD117+, CD43+ and CD45+ immunophenotype
seen in bone marrow. Similarly, Sca-1+, cKit-CD45− CD31− SP cells have been isolated
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from murine myometrium with the potential for adipogenesis and/or smooth muscle (123).
SP cells have been determined to be responsible for normal ovarian regeneration, and found
in label retaining cells in a murine model (124). Muscle derived SP cells were capable of
reconstituting the hematopoietic compartment, but not as efficiently as BM derived SP cells,
suggesting the importance of micro-environmental factors on plasticity-related SP cell
function (125). SP cells have also been isolated from adult rat kidney (126), murine liver
(127) testis (128), skin (129) and mammary gland (130). SP cells have been isolated from
adult human peripheral blood and characterized expressing relatively high levels of CD45,
CD59, CD43+, CD49d, CD31and lacking CD34. Functional studies in immunodeficient
mice and in-vitro assays suggested that these cells were further differentiated relative to
multipotent murine marrow SP cells, only giving rise to lymphoid cells (25). It is possible
that hematopoietic multipotential capacity might reside within ALDH+ CD34- cells rather
than the SP CD34- cell compartment, in humans (131).
At this time, it is appears that isolation of SPcells from these various tissues seems to enrich
for residenttissue stem or progenitor cells, but not necessarily exclusively so. Recent
advances in two-photon microscopy and software permit the study of SP cells in tissue
culture, opening up their microenvironmental interactions in heterogeneous cultures without
disruption (132). With further such in-situ study, increased clarification of the role of SP
cells in development will hopefully become further evident.
Rhodamine 123—Rhodamine 123 is a non-toxic lipophilic cationic fluorescent dye which
binds within the mitochondria of living cells, and similar to Hoechst is effluxed efficiently
by a p-glycoprotein/ATP transporter. It has been used in experiments with Hoechst 33342 to
identify and separate long term repopulating cells from murine bone marrow (133).
Cell Tracking, Proliferation, Signaling & Reporter Genes
The lipophilic membrane binding PKH and protein-binding CSFE (carboxyfluorescein
diacetate, succinimidyl ester) dyes (Table 1) have been found to be useful for in vitro cell
labeling, in vitro proliferation studies and long term, in vivo cell tracking. Upon entering
cells, these dyes diffuse throughout the cell membrane (PKH) or cytoplasm (CSFE). As the
cells divide, the fluorescent emissions are split equally between the daughter cells resulting
in diminished signal detection by flow cytometry. This division, and resultant signal
reduction occurs with each subsequent cell division. The ability to track cell division in
conjunction with cell surface markers affords stem cell researchers with an essential tool to
study experimental populations over time
Green fluorescent protein (GFP) is a 238 amino acid protein obtained initially from the
bioluminescent jellyfish Aequorea victoria, whose gene can be introduced by viral vector or
local injection into organisms (134). This has been very useful as a reporter gene, and many
mammalian and non-mammalian cells have been created using GFP as a marker, although
caution is warranted regarding strain specificity, resistance to fixation and it’s lack of
ubiquitous penetration into all tissue (135). Homologous proteins with disparate spectral
characteristics including cyan (CFP) yellow-green (YFP) orange (DsRed and DsRed
Express) and orange-red (HcRed) were subsequently developed (Table 1), increasing the
available spectral breath of reporter genes for molecular studies that interface with flow
cytometry (16). It is likely that phospho-specific protein phosphorylation and cellular
signaling studies will be incorporated into the study of stem cells as these techniques mature
(136).
Cancer stem cells and Flow Cytometry—The hypothesis of cancer stem cells is based
upon the observation that not all cells derived from a tumor have the capacity to maintain
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malignant growth. Rather, there appears to be a more exclusive pool of stem cells that are
targeted by malignant transformation that are responsible for the ultimate success of the
tumor. Similar to normal stem cells, cancer stem cells have the potential to self-renew,
forming additional tumor cells of similar phenotype, while also giving rise to other tumor
cells with more limited proliferative potential. This was initially demonstrated in the context
of human acute myeloid leukemia by transplanting purified CD34bright+CD38− cells
derived from FAB characterized tumors and recovering the tumor from a NOD/SCID model
(137). Subsequent studies suggested that the putative normal human hematopoietic stem cell
expressing CD34+CD38−CD90+CD117+CD123− could be distinguished from it’s
malignant leukemic counterpart, which was CD34+CD38−CD90−CD117−CD123+ (138),
although the characterization of CD90 expression is controversial (139).
The principle of a potential leukemic stem cell was extended to findings in epithelial breast
tumors, where CD44+CD24−/low Linneg cells were found to be the tumor initiating cells
(140) and in neural tumors where CD133+ nestin+ cells were identified as brain tumor stem
cells (141). Similar to normal neural stem cells, brain cancer stem cells were determined to
reside in perivascular niches that maintained the stem-like properties of these cancer cells,
supporting an important interaction between the cell of origin and it’s microenvironment
(142). All these studies demonstrated the crucial importance of combining carefulcell
sorting with functional assays since the distinction between the tumor initiating cells was
based on specifically identified immunophenotypic differences between cell types.
Distinct from using cell surface markers, ‘functionally identified’ human SP cancer cells
have been found in the central nervous system (143,144) as well as from numerous other
tumors such as those from the hematopoietic system (145), prostate (146), ovary (147) and
gastrointestinal tract (148).
By way of caution in interpreting these and other studies based upon xenotransplantation
models, the numerous solid organ tumors described by combinations of CD44, CD24
CD133 and epithelial surface antigen (ESA) is extensive, and rather than specifying a
particular bona fide cancer stem cell, might rather enrich for cells with the functional
capacity to engraft into the immunodeficient murine model milieu often used by researchers
(149,150,151).
Conclusion
The use of flow cytometry in stem cell research requires high levels of stringency and as
‘fool-proof’ techniques as possible, since often the numbers of cell populations of interest
are relatively small, compared to those in other fields of study. Due to these small numbers
of cells, it is advantageous to take advantage of the benefits of contemporary instruments
and multiple reagent combinations to learn the maximum possible about these populations.
The new software tools described in this review should further aid these endeavors.
While the convergence of improved hardware, reagents and software permit this capacity,
the techniques to reproducibly stain cells with numerous directly conjugated fluorochromes
is not yet at a “turn-key” stage. Simply consulting a table of dye excitation and emission
maxima and matching these to band-pass filter specifications and excitation sources are the
first step, but itself insufficient to achieve reliable polychromatic capacity. Initial problems,
such as potential dye-dye interactions on the surface of cells, the stability of tandem
conjugates, changes in background staining and potential cell-surface antigen steric
problems need to be fully understood. While the need for calibration controls and
compensation matrices presently require far more care than routine 4-color work, most of
these obstacles have been sufficiently surmounted.
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A variety of issues must be considered to bring reliable polychromatic flow cytometry into
routine use in the stem cell laboratory. For example, certain cyanine dyes non-specifically
stick to B-cells and macrophages and thus must be carefully utilized if these cells are
present. The newly available Alexa dyes may serve as suitable substitutes for the cyanine
dyes. It is important to remember that manufactured lots of tandem-conjugated antibodies
may have disparate compensation needs due to variable ratios of donor and acceptor
molecules and need be carefully monitored; improved quality control from the
manufacturers of these reagents will be welcome. In addition to cell surface staining, stem
cell analysis might require inquiry into intra-nuclear (e.g., TdT), cytoplasmic (e.g. cytokine,
activation pathway, MPO) antigens and cell signaling proteins. For these it is important to
work with good negative and positive controls. Identification and discrimination of viable
cells has recently been improved by use of the cellular amine-binding LIVE/DEAD reactive
dyes (Table 1;152). These dyes are available with a variety of excitation and associated
emission capacities, permitting their use with numerous instrument platforms when
analyzing paraformaldehyde fixed cells. The nucleic-acid binding propidium iodide,
ethidium monoazide, 7-aminoactinomycin-D, DAPI or cytoplasmic membrane specific
phosphatidylserine ligands (annexin V) remain useful viability reagents for live cell sorting.
From a practical perspective, there are numerous worthwhile advantages to perfecting a
polychromatic staining protocol, over more typical 4-color staining protocols. These include
obtaining improved data from hypo-cellular specimens, increased information about
antigenic co-expression and the built-in quality control of multiple markers present in the
same staining tube. From a reagent cost-containment perspective, the need to duplicate the
use of monoclonal antibodies in large four-color panels is obviated when unconstrained to a
4-color limitation; this also results in overall decrease in the use of ancillary staining [e.g.
lyse, fixation] reagents. The need to use fewer staining tubes per sample will result in an
overall increase in cytometer throughput, although post-acquisition analysis is increased.
Routine ‘CD45 gating’ to exclude erythrocytes and debris from viable leukocytes also
becomes a more realistic and cost effective option when there are numerous
immunofluorescent parameters to work with. Finally, cell function, specificity and state of
activation may be more easily understood by simultaneously incorporating flow-based cell-
cycle, proliferation, cytokine and tetramer expression studies into polychromatic staining
protocols.
It is important to appreciate that the goal of polychromatic cytometry and described new
advanced instruments analytical tools is to simplify and enhance the understanding of stem
cells. The information content available increases geometrically with each additional
parameter and uncovers co-expressions otherwise unavailable to the cell biologist. The
cytometric community needs to take the lead in the exploration and introduction of the new
hardware, reagent and software tools newly available to us. It is felt the advantages of
polychromatic cytometry far outweigh some present problems, which are surmountable. It is
also worthwhile to note that new technologies such as the Amnis Image Stream expand the
breath of information available to traditional flow cytometry. Simply put, it is good research
practice to obtain the increased depth of information possibly by implementing these new
technologies. We feel that the quality of data presented here demonstrates their practical
feasibility, proof-of-principle and future possibilities.
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Figure 1. Thermo-Immunology
Demonstration of infra-red excitation of CD4 (left) and CD8 (right) monoclonal antibodies
directly conjugated with LI-COR IR800 and captured by an infra-red selected Hamamatsu
R3896MOD PMT. Peripheral blood was additionally stained with CD3-APC and CD45-
FITC. This novel excitation line increases the repertoire of monoclonal antibody conjugate
pairing available to the cytometrists and can also be used with infra-red excitable tracking
dyes.
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Figure 2. 7-Laser optical bench configuration
This experimental design platform permits multiple air-cooled lasers to be placed within a
modestly sized laboratory benchtop configuration. Each of the lasers has independent
steering optics that permits each beam to be accurately focused into the instrument’s flow
cell [lower right]. The power and wavelength of each laser, and the number of PMTs utilized
is shown on the accompanying table.
Laser Wavelength [nm] Style Power [mw] PMT Array PMT#
1 UV 355 Mode Lock 20 Trigon 2
2 Violet 405 Diode Pumped Solid State 50 Octagon 8
3 Blue 488 Diode Pumped Solid State 20–100 Octagon 4
4 Green 532 Diode Pumped Solid State 40–150 Octagon 5
5 Yellow 594 Diode Pumped Solid State 50 Trigon 2
6 Red 638 Diode Pumped Solid State 40 Trigon 3
7 IR 785 Diode Pumped Solid State 25 Trigon 1
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Figure 3. Reduced Spillover Using More Excitation Lines
Signal resolution for CD3 versus CD4 is much improved by excitation of 3 conjugated
antibodies with three discreet light sources (left, 405nm, 532nm, 638nm for CD3-Pacific
Blue, CD8-PE and CD4-APC) compared to one (right, 405nm for CD3-Pacific Blue, CD4-
Amcyan and CD8-Pacific Orange).
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Figure 4. Parallel Coordinate Plots
Shown are four inter-related 3-dimensional parallel coordinate plots of a 1.5×106 event data
file, gated initially on forward and side light scatter (Panel A), prior to omission of
Lineagepos cells, leaving remaining Lineagelow and Lineageneg for further analysis (Panels
B–D). Panel A represents total bone marrow cells; B are gated Lineagelow-neg bone marrow
cells; C are Lineagelow-neg cKit+Sca-1+ cells; D are Lineagelow-neg FLK2+ cells. Mouse
bone marrow cells were stained with titered concentrations of CD34-FITC, CD16/32-
Alexa700, cKit--APC, Sca-1-PECy5.5, FLK2-PE, IL-7-Pacific Blue and a murine lineage
cocktail, consisting of biotinylated CD3, CD4, CD8, Mo2, Gr-1, Ter119, B220/CD45R and
developed with streptavadin-PerCP. Panel A provides an overview of the relationships
shown in 42 bivariate plots.
Parallel coordinates of immunofluorescent parameters are depicted on the x-axis,
logarithmic fluorescent channel number intensity on y-axis, and the density of distributions
on z-axis. To interpret the plots, one follows the relationship of antigenic co-expression
across all parameters on the x-axis, the correlated fluorescent intensity of each parameter on
the y-axis and the numbers of events depicted on the z-axis. For example, in looking across
the x-axis of Panel C, as a result of cKit+Sca-1 gating, there is uniform expression of CD34,
Lineageneg, relatively high expression of CD16/32, robust expression of cKit and Sca-1 and
bimodal expression of Flk2 and Il7R. There is a more complex relationship of the data in
Panel D, which represents Lineage low-neg followed by selection of FLK2+ cells. Looking
across parameters one sees uniform levels of CD34, two levels of Lineage low-neg, 2 two
levels of CD16/32, negative and positive cKit and Sca-1 subpopulations, and two levels of
IL7R expression.
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Figure 5. Polyvariate Plot
The mouse bone marrow sample described in Figure 4 was re-plotted as a 7 vector FlowJo
Polyvariate plot. Vectors are arranged in a star pattern to provide identification of each
monoclonal antibody -fluorochrome combination around a common central point. The
arrangement of these fluorochrome conjugated antibodies is displayed by the colored lines
displayed around a central point, and the histogram pivot range is displayed by colored
histograms. The resulting Polyvariate Plot demonstrates the correlation of all seven
parameters on one 2-dimensional plot, rather than numerous bivariate plots.
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Figure 6. Probability State Model of Human B-Cell Maturation
Human bone marrow was stained with titered volumes of CD23-Pacific Blue, CD20-
AmCyan, TdT-FITC, CD34-PerCP, CD43-PE, CD19-PeCy5.5, CD10-PECy7, Kappa –
APC, CD45-APCCy7and Lambda- Alexa 594. Approximately 10,000 cells were analyzed
and depicted in this Figure. The percentage of cells in each ‘state’ can be measured along the
x-axis, and the level of antigen expression measured along the y-axis, where discreet colors
are assigned to each parameter. B-cell precursors are seen to be down-regulating ‘early’
markers like CD34 and TdT and up-regulating more ‘mature’ antigens like CD20, CD23 and
surface immunoglobulin light chain. These correlated variations are intuitively
comprehensible since they are similar to the way a user might diagram the data. In contrast
to the necessity of numerous conventional bivariate plots, Gemstone™ concisely depicts all
these relationships in one plot.
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Figure 7. Side Population cells from Fallopian Tube
Cells isolated from benign human infundibular- fallopian tube biopsy freed with 1 hour
incubation in collagenase were suspended in 1%Fcs DMEM and 5 ug/ml Hoechst 33342 for
1.5 hours at 37 C. Cells were re suspended in cold 1%FCS PBS and stained with four
additional surface markers (not shown) for 15 minutes on ice and washed and re-suspended
in 1%FCS PBS and stained with 7AAD and run on the author’s multiple laser analyzer.
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Table 1
Useful Fluorescent Probes and their Spectral Characteristics
Fluorochrome Excitation Max(nm) Excitation Lines(nm) Emission Max(nm) Emission Color
Propidium iodide 305, 540 350–360, 488 620 Yellow- Orange
Indo-1 Ca bound 330 350–360 405 Violet
Indo-1 Ca free 346 350–360 480 Blue
LIVE/DEAD blue 350 350–360 450 Blue
Hoechst 33342 352 350–360 455 Blue
AMCA-X 353 350–360 442 Blue
DAPI 359 350–360 461 Blue
Marina Blue 365 350–360 460 Blue
Alexa Fluor 350 346 350–360 442 Blue
Pacific Orange 400 405,407 551 Blue
Pacific Blue 404 405,407 456 Blue
BD Horizon V450 404 405,407 452 Blue
LIVE/DEAD violet 416 405,407 451 Blue
Alexa Fluor 405 405 405,407 420 Violet/Blue
ECFP 434 458,488 477 Blue
AmCyan 458 405,407 489 Blue
EGFP 489 458,488 508 Cyan
Alexa Fluor 430 430 405,407 540 Green
CFSE 490 488 518 Green
PKH2 & PKH67 490 488 504 Green
LIVE/DEAD green 495 488 520 Green
Alexa Fluor 488 495 488 519 Green
FITC 494 488 519 Green
Rhodamine 123 507 488 529 Yellow-Green
Ethidium monoazide 510 488 600 Yellow- Orange
EYFP 514 488,532 527 Yellow-Green
Alexa Fluor 532 531 532 554 Yellow-Green
PKH26 551 488,532 567 Yellow-Green
DsRed 558 568 583 Yellow
PE 496,546 488,532 578 Yellow
PE-Texas Red 496,546 488,532 615 Yellow- Orange
HcRed 588 532,568,590,594 618 Yellow- Orange
Alexa Fluor 594 590 594 617 Yellow- Orange
LIVE/DEAD red 595 488 615 Yellow- Orange
Texas Red 595 595 615 Yellow- Orange
7-AAD 550 488,532,594 660 Red
DRAQ5 646 633 681 Red
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Fluorochrome Excitation Max(nm) Excitation Lines(nm) Emission Max(nm) Emission Color
APC 650 595,633,635,647 660 Red
Alexa Fluor 647 650 595,633,635,647 668 Red
PE-Cy5 496,546 488,532 667 Red
Cy5 640 633,635 670 Red
PerCP 482 488,532 678 Red
Alexa Fluor 660 663 647 690 Red
LIVE/DEAD far red 650 633,635 665 Red
APC-Cy5.5 650 633,635 694 Red
PerCP-Cy5.5 482 488,532 695 Red
PE-Cy7 496,546 488,532 785 InfraRed
APC-Cy7 650 595,633,635,647 785 InfraRed
APC-Alexa Flour 750 650 595,633,635,647 775 InfraRed
HiLyte 750, no tandem 753 785 778 InfraRed
IRDye 800CW 774 785 789 InfraRed
Q-dots/eFluor/AxiCad various 350–360, 407 various Various
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Table 2
Antigen Other Names Differentiated Cell Expression Stem/Progenitor Expression
CD34 8G12, 581, QBEnd10 endothelial HSC
CD105 Endoglin endothelial, macrophage/monocyte mesenchymal, with CD73+, CD16+, CD90+
CD29+ CD34−, CD45−, Lin−
CD90 Thy-1 murine pan T, thymocyte, fibroblast murine hematopoietic, neural
CD117 c-kit, steel, stem cell factor breast epithelial, renal tubule,
melanocytes
myeloid, HSC
CD133 AC133, Prominin-1 endothelium, epithelial HSC, endothelial, and neural epithelial
CD135 FMS-like kinase-3 (FLT3) or
STK-1, or Flk-2
macrophage/monocytes human marrow CD34+ & dendritic
precursors, murine short-term -HSC
CD150 SLAMf1; used with CD244 and
CD48
T,B, dendritic, endothelial distinguishes HSC from multipotent and B
cell progenitors
SCA-1 stem cell antigen; when used with
cKit and Lin- the combination is
‘ LKS’
HSC
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